HitGen is focusing our innovative ability on discovering novel therapies that will make a real difference to patients with cancer or Inflammatory diseases. We have developed a broad and deep pipeline of both wholly owned and partnered therapeutics candidates. Our pipeline includes both small molecule and nucleic acid drug drugs.
Class I/IIb selective HDAC inhibitor, capsule
Class I/IIb selective HDAC inhibitor, capsule
2nd generation NTRK/ROS1 inhibitor, tablet
2nd generation STING agonist, iv
Menin-MLL, tablet
PROTAC
Immuno-oncology
Transcriptomics
Kinase inhibitor
Synthetic lethal
Synthetic lethal
Immuno-oncology
Small molecule inhibitor for IL-17a, po
ROCK2 inhibitor,eye drop
We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for
More information